Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

Published Date: 08 Sep 2025

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

AI catches one-third of interval breast cancers missed at screening

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot